Hanmi Science Co., Ltd. (KRX:008930)
44,500
+2,400 (5.70%)
Aug 28, 2026, 3:30 PM KST
Hanmi Science Revenue
Hanmi Science had revenue of 367.86B KRW in the quarter ending June 30, 2026, with 8.75% growth. This brings the company's revenue in the last twelve months to 1.41T, up 10.00% year-over-year. In the year 2025, Hanmi Science had annual revenue of 1.36T with 5.73% growth.
Revenue (ttm)
1.41T
Revenue Growth
+10.00%
P/S Ratio
2.14
Revenue / Employee
2.96B
Employees
476
Market Cap
3.01T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.36T | 73.53B | 5.73% |
| Dec 31, 2024 | 1.28T | 35.53B | 2.85% |
| Dec 31, 2023 | 1.25T | 201.85B | 19.30% |
| Dec 31, 2022 | 1.05T | 95.89B | 10.09% |
| Dec 31, 2021 | 950.16B | 92.78B | 10.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.12T |
| Celltrion | 4.90T |
| Samsung Epis Holdings | 1.51T |
| SK bioscience | 659.27B |
| Hugel | 479.57B |
| ST Pharm | 346.22B |
| ALTEOGEN | 203.76B |
| Hanall Biopharma | 162.66B |